22. January 2021

Clinical Validation of an Automated Fluorogenic FXIII Activity Assay



Zedira kits


Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | January 2021



Dear Transglutaminase researchers,

On January 20th 2021, Technoclone (Vienna, Austria) and Zedira published the second joint paper entitled "Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity".

The paper was published in the International Journal of Molecular Sciences as part of the Special Issue Fibrinogen/Fibrin, Factor XIII and Fibrinolysis in Diseases. The accurate, rapid, and precise assay is meant to improve routine diagnostics and therefore should help patients, physicians, and researchers.

At Zedira, we are scientists at heart. Cutting edge science and technology are mandatory for entrepreneurial success in the biotech business. Besides tissue transglutaminase, our research focused on coagulation factor XIII for already about two decades by now.
Our proprietary compound ZED3197 showed the proof-of-principle of “safe” anticoagulation therapy. Specific inhibition of FXIIIa allows unprecedented intervention in the coagulation cascade (published in Journal of Thrombosis and Haemostasis as Open access paper).

We are happy to share with you our exclusive products to support your esteemed research & development. Please find bellow a collection of our most important FXIII related tools.


FXIII

Art. No. Name Unit Price

T027

Human blood coagulation Factor XIII-A2, recombinant
(hFXIII, A subunit, recombinantly produced in insect cells)

200 µg 370 €
T070

Human Factor XIIIa, Thrombin activated
(hFXIIIa, recombinantly produced in insect cells)


200 µg 520 €
T050

Human blood coagulation Factor XIII B subunit
(hFXIII B, F13B, recombinantly produced in insect cells)

200 µg 370 €

Assays and Substrates

Art. No. Name Unit Price

A101

FXIII-Assay Substance,
Abz-NE(CAD-DNP)EQVSPLTLLK-OH

10 mg
520 €
F001

FXIII-Assay Kit
(ready to use, contains A101 and thrombin)

1 Kit
575 €

Inhibitors

Art. No. Name Unit Price

T101

1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride

10 mg
480 €
A108

Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH
(Synonym ZED1301, site specific irreversible inhibitor of FXIII)

5 mg
480 €


NEW

Art. No. Name Unit Price

T222

Human Alpha Thrombin, recombinant

100 NIH Units 185 €


Antibodies

Art. No. Name Unit Price

A016

Polyclonal antibody to human factor XIII (A-subunit)

500 µg
365 €
A032

FITC-labeled polyclonal antibody to human factor XIII (A-subunit)

200 µg
395 €
A074 Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09)

200 µg 365 €
A077
FITC-labeled polyclonal antibody to human factor XIII (B-subunit)
 
200 µg 365 €
A076

"DD-XLink-mab"
Monoclonal antibody against crosslinked fibrin ("D-dimer")
100 µg
365 €




Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA